✦ LIBER ✦

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia: II. High-dose methotrexate (HDM) in acute lymphoblastic leukemia in childhood: A pilot study from April 1981

✍ Scribed by Moe, Peter Johan ;Wesenberg, Finn ;Kolmannskog, Svein

Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 130 KB
Volume: 14
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950140316

No coin nor oath required. For personal study only.

✦ Synopsis

The pilot study using HDM in all cases of ALL in childhood had been run for 4 112 years as of September 1985. Fourteen (23%) of all 62 diagnosed cases of ALL had WBC above 50 x 109/L, all 14 achieved CR. Three of them were below one year of age, two also had WBC above 400 x 109/L, the third infant had Bcellleukemia. The remaining 11 children received o u r new HDM protocol (Fig. I), one of them had relapsed (BM) as of September 1985.

📜 SIMILAR VOLUMES

Methotrexate infusions in poor prognosis

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, august 1975-December 1980

✍ Moe, Peter Johan ;Seip, Martin ;Finne, Per H. ;Kolmannskog, Svein 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

One hundred fifty-three children with ALL were diagnosed in Norway in the period August 1975-December 1980. One hundred ond remission. thirty-two of them received 3 infusions of methotrexate as consolidation therapy combined with methotrexate intrathecally as CNS prophylaxis. Eleven (44%) of the tot

Randomized comparison of moderate-dose m

Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group study

✍ Lange, Beverly J.; Blatt, Julie; Sather, Harland N.; Meadows, Anna T. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

Methotrexate (MTX) infusions of 500-1,000 mg/m2 over 24 hours may improve survival and prevent relapse in children with acute lymphoblastic leukemia (ALL). Childrens Cancer Group (CCG) Study 139 compared weekly oral methotrexate 20 mg/m2/ week (oral MTX) to MTX 500 mg/m2 infused over 24 hours (IV MT

A pilot study of intermediate-dose metho

A pilot study of intermediate-dose methotrexate and cytosine arabinoside, “Spread-out” or “Up-front,” in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia a pediatric oncology group study

✍ Robert A. Krance; Edward M. Newman; Donald Pinkel; Yaddanapudi Ravindranath; Mic 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

One hundred six children with newly diagnosed non-T-, non-B-cell acute lymphoblastic leukemia (ALL) were treated in a Pediatric Oncology Group (POG) pilot study in which six courses of intermediate-dose methotrexate (MTX) and cytosine arabinoside (Ara-C) (1 g/m2 each) were added to a "backbone" of s